Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Dec 3, 2021
18th Global Cardiovascular Clinical Trialists Forum
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
Dec 2, 2021 1:00 PM EST
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 30, 2021
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 22, 2021 4:30 PM EST
Arrowhead Pharmaceuticals 2021 Year End Results
Nov 16, 2021 11:50 AM EST
Jefferies London Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 13 - Nov 17, 2021
American Heart Association (AHA) Scientific Sessions 2021

Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders

Nov 12 - Nov 15, 2021
The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

Title: ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression
Authors: Pavel Strnad, et al.
Publication Number: LP11
Session: Late-breaking Abstract Posters

Title: ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH
Authors: Lung-Yi Mak, et al.
Publication Number: LP13
Session: Late-breaking Abstract Posters

Title: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study
Authors: Man Fung Yuen, et al.
Publication Number: LO10
Session: Late Breaking Session 2

Oct 26, 2021 3:00 PM EDT
ARO-C3 KOL Webinar
Oct 12, 2021 2:00 PM EDT
H.C. Wainwright 5th Annual NASH Investor Conference
James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine will participate in a fireside chat presentation
Oct 4, 2021 4:30 PM EDT
Chardan's 5th Annual Genetic Medicines Conference
Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation